472 related articles for article (PubMed ID: 33168453)
1. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
3. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
4. Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.
Niu C; Jin H; Li M; Zhu S; Zhou L; Jin F; Zhou Y; Xu D; Xu J; Zhao L; Hao S; Li W; Cui J
Oncotarget; 2017 Jan; 8(4):5954-5964. PubMed ID: 27992381
[TBL] [Abstract][Full Text] [Related]
5. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
[TBL] [Abstract][Full Text] [Related]
6. Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells
Wang Z; Wang Z; Li S; Li B; Sun L; Li H; Lin P; Wang S; Teng W; Zhou X; Ye Z
Front Immunol; 2018; 9():1239. PubMed ID: 29910819
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
8. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
9. NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells.
Dokouhaki P; Schuh NW; Joe B; Allen CA; Der SD; Tsao MS; Zhang L
Eur J Immunol; 2013 Dec; 43(12):3175-82. PubMed ID: 24019170
[TBL] [Abstract][Full Text] [Related]
10.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
11. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
Front Immunol; 2021; 12():651751. PubMed ID: 33868289
[TBL] [Abstract][Full Text] [Related]
12. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.
Ogbomo H; Michaelis M; Klassert D; Doerr HW; Cinatl J
Neoplasia; 2008 Dec; 10(12):1402-10. PubMed ID: 19048119
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α.
Cao G; Wang Q; Li G; Meng Z; Liu H; Tong J; Huang W; Liu Z; Jia Y; Wei J; Chi H; Yang H; Zhao L; Wu Z; Hao J; Yin Z
J Leukoc Biol; 2016 Nov; 100(5):1181-1189. PubMed ID: 27256566
[TBL] [Abstract][Full Text] [Related]
14. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.
Maniar A; Zhang X; Lin W; Gastman BR; Pauza CD; Strome SE; Chapoval AI
Blood; 2010 Sep; 116(10):1726-33. PubMed ID: 20519625
[TBL] [Abstract][Full Text] [Related]
15. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
16. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
17. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP.
Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP
Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070
[TBL] [Abstract][Full Text] [Related]
18. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.
Nanbakhsh A; Pochon C; Mallavialle A; Amsellem S; Bourhis JH; Chouaib S
Blood; 2014 Jun; 123(23):3585-95. PubMed ID: 24677544
[TBL] [Abstract][Full Text] [Related]
19. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
20. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia
Ibáñez-Navarro M; Fernández A; Escudero A; Esteso G; Campos-Silva C; Navarro-Aguadero MÁ; Leivas A; Caracuel BR; Rodríguez-Antolín C; Ortiz A; Navarro-Zapata A; Mestre-Durán C; Izquierdo M; Balaguer-Pérez M; Ferreras C; Martínez-López J; Valés-Gómez M; Pérez-Martínez A; Fernández L
Front Immunol; 2023; 14():1187665. PubMed ID: 37928520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
